Comparison of long-term outcome between clinically high risk lobular versus ductal breast cancer: a propensity score matched study.

ABSTRACT:

Background

Abemaciclib is currently approved for the adjuvant treatment of high-risk, lymph node (LN)-positive, hormone receptor (HR)-positive breast cancer (BC). In a real-world setting the clinicopathologic features of patients potentially eligible for adjuvant abemaciclib remain to be defined. There are conflicting data regarding the biological behavior and long-term outcomes across invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC). In our study we retrospectively assessed the real-world data and long-term outcome of selected high-risk features ILC compared to IDC, according to the MonarchE trial inclusion criteria.

Methods

We identified 15,071 patients who got surgery at the European Institute of Oncology for a first primary, non-metastatic, HR-positiv

SUBMITTER: Magnoni F 

PROVIDER: S-EPMC10965498 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature